Celnovte Biotechnology

Behind the scenes at Celnovte! Walk into the our Factory and Lab. #QualityMatters #lab #Pathology #histologytechnician #manufacture #ivd #celnovte #immunohistochemistry #factory

We are thrilled to invite you to meet Celnovte Biotech in Dubai World Trade Centre at the Medlab Medical Laboratory Industry Forum on 3 - 6 February, 2025, Booth Z2.D23! Let’s connect and discuss how we can collaborate to advance pathology diagnostics. 📆 Date: 3 - 6 February, 2025 🔢 Booth: Z2. D23 📍 Venue: Dubai World Trade Centre

Optimize your #IHC lab workflow with the #CNT300-Automatic IHC Slide Stainer. This advanced system supports continuous operation, loading up to 30 slides across three independent frames simultaneously. Enjoy a fully automated process, including slice drying, deparaffination, antigen retrieval, and more, enhancing lab standardization and efficiency.

Celnovte attended #NordiQC for the past 10 years. Till now, we have 36 Primary antibody won optimal in NordiQC assessment.

Wish you a Merry Christmas and a Happy New Year!

🔬 Celnovte's PD-L1 (C9C9) Antibody Achieves Optimal Performance in NordiQC Assessment 🔬 Key usages of PD-L1 marker in IHC: - Cancer Diagnosis: Identifies PD-L1 expression in tumor tissues. - Treatment Decisions: Guides the use of immunotherapies, particularly PD-1/PD-L1 inhibitors. - Prognostic Value: Provides insights into the likely outcomes of immunotherapy. - Precision Medicine: Tailors treatments to individual patient profiles, enhancing the efficacy of targeted therapies. #Pathology #PDL1 #IHC

💉 𝐓𝐡𝐞 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐨𝐟 𝐜𝐚𝐧𝐜𝐞𝐫 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 PD-1/PD-L1 inhibitors are redefining cancer immunotherapy. ⚆ The first PD-1/PD-L1 inhibitors were approved just 10 years ago (Keytruda and Opdivo). ⚆ It’s estimated that more than 700,000 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲 have been treated with PD-1/PD-L1 inhibitors since their introduction. ⚆ The global market for PD-1/PD-L1 inhibitors is predicted to reach $110 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2031. Currently, there are 9 FDA-approved PD-1/PD-L1 inhibitors: ⚆ Keytruda (pembrolizumab) – Merck ⚆ Opdivo (nivolumab) – Bristol Myers Squibb ⚆ Tecentriq (atezolizumab) – Roche/Genentech ⚆ Imfinzi (durvalumab) – AstraZeneca ⚆ Bavencio (avelumab) – Merck Group/Pfizer ⚆ Libtayo (cemiplimab) – Regeneron/Sanofi ⚆ Jemperli (dostarlimab) – GSK ⚆ Zynyz (retifanlimab) – Incyte ⚆ Loqtorzi (toripalimab) – Coherus BioSciences/Shanghai Junshi Biosciences Co Ltd This wonderful graphic and content was created by Maryam Daneshpour 𝘞𝘩𝘢𝘵 𝘰𝘵𝘩𝘦𝘳 𝘪𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯𝘴 𝘥𝘰 𝘺𝘰𝘶 𝘵𝘩𝘪𝘯𝘬 𝘢𝘳𝘦 𝘵𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮𝘪𝘯𝘨 𝘤𝘢𝘯𝘤𝘦𝘳 𝘪𝘮𝘮𝘶𝘯𝘰𝘵𝘩𝘦𝘳𝘢𝘱𝘪𝘦𝘴? #pharma #biotech #cancer #drjojo ---------- Hi! I am Joanna, and my friends call me Dr Jojo 🌸 𝐈 𝐡𝐞𝐥𝐩 𝐬𝐭𝐚𝐫𝐭𝐮𝐩𝐬 𝐚𝐧𝐝 𝐞𝐧𝐭𝐫𝐞𝐩𝐫𝐞𝐧𝐞𝐮𝐫𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐭𝐡𝐞𝐢𝐫 𝐯𝐚𝐥𝐮𝐞 𝐚𝐧𝐝 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 ♻️ Share this if you find it interesting 🔔 Follow for insights you won't want to miss 📩 DM me to increase your visibility, grow your business, and generate leads

🏆 Celnovte Achieves No. 1 Position in Automated Immunohistochemistry (IHC) Stainer Installations via New Tenders in the Greater China Market!🏆 We’re thrilled to share that Celnovte has emerged as a market leader in the automated IHC stainer, according to public tender data from January to September 2024. Key Highlights from the Report: 📊 New Tenders Market Share: Celnovte, along with Roche and Leica, accounted for 43% of the total market share, with Celnovte leading at 14.78%. 💡 Top Models: Celnovte’s innovative models like CNT360-M1, CNT300, and CNT330 continue to set the benchmark for quality and reliability in automated staining solutions. This achievement is a testament to the dedication of our team, the trust of our partners, and our relentless pursuit of excellence in pathological diagnostics. We look forward to continuing to serve our customers with cutting-edge solutions that drive efficiency and accuracy in laboratories across the region. 🔬 Empowering pathology, advancing healthcare. #Celnovte #Pathology #Immunohistochemistry #ihcstainer

Introduce MicroStacker™ RX HRP Polymer, Universal The MicroStacker™ RX HRP Polymer Universal is a versatile detection reagent, suitable for both mouse and rabbit primary antibodies on human tissue. It combines flexibility with high performance for a wide range of IHC applications. Key Features: 1. Dual Antibody Detection: Compatible with both mouse and rabbit primary antibodies. 2. Superior Sensitivity: Achieves enhanced clarity and reduced background noise. 3. Streamlined Process: Manual one-step method ensures ease of use and efficiency. Recommended Protocol: • Primary Antibody Incubation: RT, 30–60 minutes • Detection Polymer Application: RT, 30 minutes • DAB Chromogen Reaction: 5 minutes https://lnkd.in/giHngScq #Polymer #pathology

Introduce MicroStacker™ RX HRP Polymer, Universal The MicroStacker™ RX HRP Polymer Universal is a versatile detection reagent, suitable for both mouse and rabbit primary antibodies on human tissue. It combines flexibility with high performance for a wide range of IHC applications. Key Features: 1. Dual Antibody Detection: Compatible with both mouse and rabbit primary antibodies. 2. Superior Sensitivity: Achieves enhanced clarity and reduced background noise. 3. Streamlined Process: Manual one-step method ensures ease of use and efficiency. Recommended Protocol: • Primary Antibody Incubation: RT, 30–60 minutes • Detection Polymer Application: RT, 30 minutes • DAB Chromogen Reaction: 5 minutes https://lnkd.in/giHngScq #Polymer #pathology